J
John J. Seaman
Researcher at Novartis
Publications - 38
Citations - 9199
John J. Seaman is an academic researcher from Novartis. The author has contributed to research in topics: Zoledronic acid & Pamidronic acid. The author has an hindex of 23, co-authored 38 publications receiving 8937 citations. Previous affiliations of John J. Seaman include Yorkshire Cancer Research & University of California, Los Angeles.
Papers
More filters
Journal ArticleDOI
Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple Myeloma
James R. Berenson,Alan Lichtenstein,Lester Porter,Meletios A. Dimopoulos,Roldolfo Bordoni,Sebastian George,Allan Lipton,Alan Keller,O. F. Ballester,Michael J. Kovacs,Hilary A. Blacklock,Richard Bell,Joseph F. Simeone,Dirk J. Reitsma,Maika Heffernan,John J. Seaman,Robert Knight +16 more
TL;DR: Monthly infusions of pamidronate provide significant protection against skeletal complications and improve the quality of life of patients with stage III multiple myeloma.
Journal ArticleDOI
Efficacy of Pamidronate in Reducing Skeletal Complications in Patients with Breast Cancer and Lytic Bone Metastases
Gabriel N. Hortobagyi,R. L. Theriault,Lester Porter,Douglas W. Blayney,Allan Lipton,Clive Sinoff,Helen Wheeler,Joseph F. Simeone,John J. Seaman,Robert Knight,Maika Heffernan,Dirk J. Reitsma,Ian Kennedy,Simon G. Allan,Kathleen Mellars +14 more
TL;DR: In this paper, pamidronate disodium (90 mg) was given to women with stage IV breast cancer who were receiving cytotoxic chemotherapy and had at least one lytic bone lesion.
Journal Article
Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial.
Lee S. Rosen,David Gordon,Mary Kaminski,Anthony Howell,Andrew R. Belch,John R. Mackey,J. Apffelstaedt,Mohamed Hussein,Robert E. Coleman,Dirk J. Reitsma,John J. Seaman,Bee Lian Chen,Yvonne Ambros +12 more
TL;DR: Zoledronic acid (4 mg) via 15-minute intravenous infusion was as effective and well tolerated as 90 mg of pamidronate in the treatment of osteolytic and mixed bone metastases/lesions in patients with advanced breast cancer or multiple myeloma.
Journal ArticleDOI
Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial.
Lee S. Rosen,David Gordon,Mary Kaminski,Anthony Howell,Andrew R. Belch,John R. Mackey,J. Apffelstaedt,Mohamad A. Hussein,Robert E. Coleman,Dirk J. Reitsma,Bee-Lian Chen,John J. Seaman +11 more
TL;DR: In this article, the authors compared the long-term safety and efficacy of zoledronic acid with pamidronate in patients with bone lesions secondary to advanced breast carcinoma or multiple myeloma.
Journal ArticleDOI
Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group.
Lee S. Rosen,David Gordon,Simon Tchekmedyian,Ronald Yanagihara,Vera Hirsh,Maciej Krzakowski,Marek Pawlicki,Paul de Souza,Ming Zheng,Gladys Urbanowitz,Dirk J. Reitsma,John J. Seaman +11 more
TL;DR: Zoledronic acid (4 mg infused over 15 minutes) is the first bisphosphonate to reduce skeletal complications in patients with bone metastases from solid tumors other than breast and prostate cancer.